On the “Fast Track”: Fast Track Designations for Your 505(b)(2) Drug Development Program

One of the tenets of the FDA is to get safe and effective drugs to market as soon as possible. To expedite products where there is the greatest clinical need, the FDA offers 4 expedited programs to get beneficial therapies to patients faster: Priority Review, Accelerated Approval, Breakthrough Therapy Designation, and Fast Track Designation. In this blog, we will focus on the details of Fast Track Designation (FTD) and how 505(b)(2) products can qualify for this program.

Fast Track Designation History

The roots of expedited programs like FTD date back to the AIDS crisis of the 1980s, when there were no established or FDA-approved treatments for HIV/AIDS. Under the development framework at the time, there were incredibly long timelines for drug approval. Therapies under development for HIV/AIDS, like zidovudine (better known as AZT), could not meet the risk-benefit requirements. Patients and caregivers were outraged and began to seek out any treatment that had anecdotal evidence of efficacy, regardless of risk.

This time led to many important changes at the Agency, most notably PDUFA, as well as a recognition of the difference in risk-benefit threshold of patients with life-threatening and debilitating diseases. The prioritization of applications was amended to reflect this view. The first expedited programs, priority review and accelerated approval, were created in 1992 to shorten the timelines for demonstration of therapeutic efficacy (through use of surrogate markers) and reduce the timeframe of NDA review by FDA.

While priority review and accelerated approval benefit late stage development, Fast Track Designation (introduced in the Food and Drug Modernization Act of 1997) offers an expedited program for products at an earlier stage of development.

Fast Track Designation Criteria

As described in Section 506 (b) of the FD&C Act, a product can be designated as a fast track product “if it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition.”

At Camargo, we’re often asked if 505(b)(2) programs can qualify for FTD, and the answer is yes. Any product, independent of its 505(b)(1) or 505(b)(2) classification is eligible for this program. As described in detail below, as long as the product is being made for a serious condition with the potential to address an unmet medical need, it can be granted FTD.

The qualifying criteria for a FTD are the following:

Serious Condition:

The FDA considers a condition “serious” when it has a substantial impact on day to day functioning, survival, or if the condition (if left untreated) will progress in severity. The drug under development must have an effect on the condition itself or a serious aspect of the condition. This can include any of the following:

• A direct effect on the serious condition
• A diagnostic product intended to improve diagnosis or detection of a serious condition in a way that would lead to improved outcomes
• A product intended to mitigate or prevent a serious treatment-related side effect
• A product intended to avoid or diminish a serious adverse event associated with available therapy for a serious condition
• A product intended to prevent a serious condition or reduce the likelihood that condition will progress to a more serious condition or a more advanced stage of disease

Address an Unmet Medical Need:

The FDA considers an unmet medical need one “whose treatment or diagnosis is not addressed adequately by available therapy.” The FDA makes the following considerations when determining if a drug will address an unmet medical need:

1. Currently no available therapy: If there is no available therapy, clearly there is an unmet need.
2. Therapy for the serious condition exists: If there is a current treatment for the serious condition, FTD is still possible. A new treatment would address an unmet medical need if the treatment:
   • Has an effect on a serious outcome of the condition that is not known to be influenced by available therapy
   • Has an improved effect on a serious outcome of the condition compared with available therapy
   • Has an effect on a serious outcome of the condition in patients who are unable to tolerate or failed to respond to available therapy
   • Can be used effectively with other critical agents that cannot be combined with available therapy
   • Provides efficacy comparable to the available therapy while avoiding serious toxicity that occurs with available therapy, avoiding serious toxicity that is common and causes discontinuation of treatment of a serious condition, or reducing the potential for harmful drug interactions
   • Provides safety and efficacy comparable to available therapy but has a documented benefit (such as improved compliance) that is expected to lead to an improvement in the serious condition
   • Addresses an emerging or anticipated public health need (such as a drug shortage)
3. Therapy for the serious condition was approved based on a surrogate endpoint: For treatments approved under Accelerated Approval (meaning a surrogate endpoint was used as the basis of efficacy), if clinical benefit has not yet been confirmed in postapproval studies, new products for the same serious condition will be considered for FTD.

The amount of information needed to demonstrate that the product addresses an unmet medical need will depend on the product stage of development. Notably, if the product is early in development, data from nonclinical models, pharmacologic data, or a mechanistic rationale can be used. If the product is in more advanced stages of development, clinical data may be needed to demonstrate the potential to address an unmet medical need.

Fast Track Designation Application Timeline

FTD can be requested as early as the IND. FTD can also be requested anytime thereafter, although ideally no later than the pre-NDA (or pre-BLA) meeting.

Fast Track Designation Response Time

The FDA response time for FTD is within 60 calendar days of receipt of the request.

Fast Track Designation Benefits

Important regulatory benefits are gained with FTD. First, the development program can be accelerated through increased interactions with the FDA. In addition to pre-IND, EOP1, or EOP2 meetings to discuss key developmental issues, additional meetings with the FDA are possible and can be scheduled as appropriate. Additionally, the product could be eligible for priority review at NDA/BLA submission if supported by the appropriate clinical data. Further, if there is preliminary evidence of clinical efficacy submitted by the Sponsor, the Agency may consider reviewing portions of the marketing application before the application is complete (known as “rolling review”).

In addition to the regulatory perks, FTD carries value for your business. A recent analysis found that the development time from IND application to FDA approval was, on average, a year shorter for FTD products than for products without this designation (Hwang, 2017).

Camargo has done 11 applications for expedited programs – all of which were 505(b)(2) programs. We have used innovative approaches to help our clients qualify for these programs, as well as help them use the regulatory benefits to their full potential.

Think your product may qualify for Fast Track Designation? Contact Camargo to discuss it with our regulatory experts. We have experience with FDA’s expedited programs and can provide guidance and expertise to determine if your program meets the requirements for Fast Track Designation. For more information, contact us.

Author:

Lisa Crose, PhD, Scientific and Regulatory Specialist, Camargo Pharmaceutical Services